{"id":"NCT01460342","sponsor":"Eli Lilly and Company","briefTitle":"Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Study to Evaluate the Efficacy and Safety of Tadalafil Once-a-day Dosing for 12 Weeks in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12","primaryCompletion":"2012-10","completion":"2012-10","firstPosted":"2011-10-26","resultsPosted":"2013-09-25","lastUpdate":"2013-09-25"},"enrollment":610,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Benign Prostatic Hyperplasia"],"interventions":[{"type":"DRUG","name":"Tadalafil","otherNames":["Cialis","LY450190"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Tadalafil","type":"EXPERIMENTAL"}],"summary":"This is a phase 3, randomized, double-blind, placebo-controlled, parallel-design, multinational study to evaluate the efficacy and safety of tadalafil once-a-day dosing for 12 weeks in Asian men with signs and symptoms of benign prostatic hyperplasia.","primaryOutcome":{"measure":"Change From Baseline in Total Score of International Prostate Symptom Score (IPSS) at 12 Weeks","timeFrame":"Baseline, 12 weeks","effectByArm":[{"arm":"Placebo","deltaMin":-4.5,"sd":0.4},{"arm":"Tadalafil","deltaMin":-6,"sd":0.4}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"45 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":27},"locations":{"siteCount":17,"countries":["Japan","South Korea"]},"refs":{"pmids":["24571205"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":304},"commonTop":["Nasopharyngitis","Headache","Dyspepsia","Blood creatine phosphokinase increased","Upper respiratory tract infection"]}}